Innovative Treatments for Mucopolysaccharidoses

Abstract

Mucopolysaccharidoses (MPSs) are caused by deficiency of specific lysosomal enzymes that affect the degradation of mucopolysaccharides or glycosaminoglycans. Since more than 15 years enzyme replacement therapies are available for an increasing number of MPSs. These therapies together with hematopoietic stem cell transplantation today are the gold standard of causal treatment in MPS. Despite confirmed efficacy, both do not cure these severe conditions. In this article, we discuss the limitations of established and promises of emerging therapies. The limitations of intravenous enzyme replacement and cell therapy can be summarized as immune reactions against the therapeutic molecules/cells and the failure to restore enduring and sufficient enzyme concentration in all relevant tissues. Accordingly, innovative approaches comprise small molecules and encapsulated cells that do not activate antitherapeutic immune reactions, several gene therapy approaches that aim for sustained enzyme expression, and new enzymes that penetrate blood–brain and other barriers for drug distribution. This article provides an update on the state of development of these new therapies and highlights enduring challenges.

Keywords

mucopolysaccharidoses - gene therapy - innovative therapies - cell therapy - pharmacology

• References

• 1 Neufeld EMJ. The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D. , eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 3421-3452
• 2 Hurler G. Über einen Typ multipler Abartungen, vorwiegend am Skelettsystem. Z Kinderheilkd 1920; 24: 220-234
• 3 Hunter C. A rare disease in two brothers. Proc R Soc Med 1917; 10 (Sect Study Dis Child): 104-116
• 4 Morquio L. Sur une forme de dystrophie osseuse familiale. Archives de medecine des infants. 1929;32:129–135
• 5 Scheie HG, Hambrick Jr GW, Barness LA. A newly recognized forme fruste of Hurler's disease (gargoylism). Am J Ophthalmol 1962; 53: 753-769
• 6 Sanfilippo S, Podosin R, Langer LJ. , et al. Mental retardation associated with acid mucpolysacchariduria (heparin sulfate type). J Pediatr 1963; 63: 837-838
• 7 Maroteaux P, Leveque B, Marie J, Lamy M. A new dysostosis with urinary elimination of chondroitin sulfate B [Article in French]. Presse Med 1963; 71: 1849-1852
• 8 Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 1973; 82 (02) 249-257
• 9 De Duve C. From cytases to lysosomes. Fed Proc 1964; 1045-1049
• 10 Brady RO. The sphingolipidoses. N Engl J Med 1966; 275: 312-318
• 11 Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968; 162 (3853): 570-572
• 12 Heartlein MWKA. Discovery and clinical development of idursulfase (Elaprase®) for the treatment of mucopolysaccharidosis II (Hunter syndrome). In: David CPM. , ed. Orphan Drugs and Rare Diseases. London: Royal Society of Chemistry; 2014: 164-182
• 13 Lenders M, Schmitz B, Brand SM, Foell D, Brand E. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol 2018; 141 (06) 2289-2292.e7
• 14 Kim S, Whitley CB, Jarnes Utz JR. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: a case report. Mol Genet Metab 2017; 122 (1–2): 92-99
• 15 Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report. J Inherit Metab Dis 2005; 28 (06) 1146-1148
• 16 Yano S, Moseley K, Pavlova Z. Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis 2009; 32 (Suppl. 01) S53-S57
• 17 Hendriksz CJ. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A syndrome). Expert Rev Clin Pharmacol 2016; 9 (12) 1521-1532
• 18 Ruane T, Haskins M, Cheng A. , et al. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations. Mol Genet Metab 2016; 117 (02) 157-163
• 19 Qi Y, Musson DG, Schweighardt B. , et al. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome. Clin Pharmacokinet 2014; 53 (12) 1137-1147
• 20 Xie H, Chung JK, Mascelli MA, McCauley TG. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. PLoS One 2015; 10 (04) e0122453
• 21 Burton BK, Berger KI, Lewis GD. , et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with Morquio A syndrome: a randomized, double-blind, pilot study. Am J Med Genet A 2015; 167A (10) 2272-2281
• 22 King B, Hassiotis S, Rozaklis T. , et al. Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. J Neurochem 2016; 137 (03) 409-422
• 23 King B, Marshall NR, Hassiotis S. , et al. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. J Inherit Metab Dis 2017; 40 (03) 443-453
• 24 Martin JJ, Ceuterick C. Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases. Clin Neuropathol 1983; 2 (03) 122-127
• 25 Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N. Prenatal mucopolysaccharidosis II (Hunter): a pathogenetic study. Pediatr Res 1980; 14 (05) 749-756
• 26 Dierenfeld AD, McEntee MF, Vogler CA. , et al. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2010; 2 (60) 60ra89
• 27 Scott CR, Elliott S, Buroker N. , et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr 2013; 163 (02) 498-503
• 28 Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 2015; 166 (01) 172-177
• 29 Mechtler TP, Stary S, Metz TF. , et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012; 379 (9813): 335-341
• 30 Munoz-Rojas MV, Vieira T, Costa R. , et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008; 146A (19) 2538-2544
• 31 Dickson P, McEntee M, Vogler C. , et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007; 91 (01) 61-68
• 32 Kakkis E, McEntee M, Vogler C. , et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004; 83 (1–2): 163-174
• 33 Kan SH, Aoyagi-Scharber M, Le SQ. , et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proc Natl Acad Sci U S A 2014; 111 (41) 14870-14875
• 34 Dickson PI, Kaitila I, Harmatz P. , et al; Mucopolysaccharidosis I Intrathecal Research Collaborative. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. Mol Genet Metab 2015; 116 (1-2): 69-74
• 35 Jones SA, Breen C, Heap F. , et al. A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 2016; 118 (03) 198-205
• 36 Muenzer J, Hendriksz CJ, Fan Z. , et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 2016; 18 (01) 73-81
• 37 Muenzer J, Burton BK, Harmatz P. , et al. Efficacy and safety of intrathecal idursulfase in pediatric patients with mucopolysaccharidosis type II and early cognitive impairment: design and methods of a controlled, randomized, phase II/III multicenter study. Mol Genet Metab 2018; 123: S99-S100
• 38 Muschol N, Cleary M, Couce ML. , et al. ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB). Mol Genet Metab 2018; 123: S102
• 39 Muenzer J, Hendriksz CJ, Stein MB, Fan Z, Kearney S, Horton J, Vijayaraghavan S, Santra S, Solanki GA, Pan L. et al. A long-term extension study evaluating intrathecal idursulfase-IT in children with Hunter syndrome and cognitive impairment. Mol Genet Metab 2017; 120: S99-S100
• 40 Study of intrathecal idursulfase-IT administered in conjunction with elaprase in pediatric patients with Hunter syndrome and early cognitive impairment available at: https://clinicaltrials.gov/ct2/show/study/NCT02055118 . Accessed March 5, 2018
• 41 Shire announces top-line results for phase II/III clinical trial in children with Hunter syndrome and cognitive impairment. Available at; https://www.shire.com/en/newsroom/2017/december/wvdwq3 . Accessed March 5, 2018
• 42 Boado RJ, Pardridge WM. Brain and organ uptake in the Rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm 2017; 14 (04) 1271-1277
• 43 Boado RJ, Hui EK, Lu JZ, Pardridge WM. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos 2012; 40 (10) 2021-2025
• 44 Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng 2014; 111 (11) 2317-2325
• 45 Boado RJ, Lu JZ, Hui EK, Pardridge WM. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosaminoglycans in Sanfilippo type A cells. Mol Pharm 2014; 11 (08) 2928-2934
• 46 Boado RJ, Lu JZ, Hui EK, Pardridge WM. Reduction in brain heparan sulfate with systemic administration of an IgG Trojan Horse-sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse. Mol Pharm 2018; 15 (02) 602-608
• 47 Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM. Insulin receptor antibody-α-N-acetylglucosaminidase fusion protein penetrates the primate blood-brain barrier and reduces glycosaminoglycans in Sanfilippo type B fibroblasts. Mol Pharm 2016; 13 (04) 1385-1392
• 48 Giugliani L, Carvalho Doni K, Poswar F, Giugliani R, Boado R. Somatic effects of AGT-181 in patients with mucopolysaccharidosisI enrolled in a phase I/II clinical trial in Brazil. Mol Genet Metab 2018; 123 (02) S53
• 49 Giugliani R, Giugliani L, Dalle Corte A. , et al. Safety and clinical efficacy of AGT-181, a brain penetrating human insulin receptor antibody-iduronidase fusion protein, in a 26-week study with pediatric patients with mucopolysaccharidosis type I. Mol Genet Metab 2018; 123 (02) S54
• 50 Mühlstein A, Gelperina S, Kreuter J. Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI. Pharmazie 2013; 68 (07) 549-554
• 51 Mayer FQ, Adorne MD, Bender EA. , et al. Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Pharm Res 2015; 32 (03) 941-954
• 52 Baldo G, Giugliani R, Matte U. Gene delivery strategies for the treatment of mucopolysaccharidoses. Expert Opin Drug Deliv 2014; 11 (03) 449-459
• 53 Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004; 6 (05) 481-506
• 54 Wakabayashi T, Shimada Y, Akiyama K. , et al. Hematopoietic stem cell gene therapy corrects neuropathic phenotype in Murine model of mucopolysaccharidosis type II. Hum Gene Ther 2015; 26 (06) 357-366
• 55 Sergijenko A, Langford-Smith A, Liao AY. , et al. Myeloid/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 2013; 21 (10) 1938-1949
• 56 Sessa M, Lorioli L, Fumagalli F. , et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016; 388 (10043): 476-487
• 57 Biffi A, Montini E, Lorioli L. , et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341 (6148): 1233158
• 58 Tardieu M, Zérah M, Husson B. , et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 2014; 25 (06) 506-516
• 59 Tardieu M, Zérah M, Gougeon ML. , et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol 2017; 16 (09) 712-720
• 60 Flanigan KM, Truxal KV, McBride KL. , et al. A phase 1/2 clinical trial of systemic gene transfer of scAAV9.U1a.HSGSH for MPS IIIA: Safety, tolerability, and preliminary evidence of biopotency. Mol Genet Metab 2018; 123: S46
• 61 Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000; 11 (15) 2117-2127
• 62 Friso A, Tomanin R, Alba S. , et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med 2005; 7 (11) 1482-1491
• 63 Baldo G, Mayer FQ, Martinelli B. , et al. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice. Cytotherapy 2012; 14 (07) 860-867
• 64 Lagranha VL, de Carvalho TG, Giugliani R, Matte U. Treatment of MPS I mice with microencapsulated cells overexpressing IDUA: effect of the prednisolone administration. J Microencapsul 2013; 30 (04) 383-389
• 65 Lizzi Lagranha V, Zambiasi Martinelli B, Baldo G. , et al. Subcutaneous implantation of microencapsulated cells overexpressing α-L-iduronidase for mucopolysaccharidosis type I treatment. J Mater Sci Mater Med 2017; 28 (03) 43
• 66 Mayer FQ, Artigalás OA, Lagranha VL. , et al. Chloramphenicol enhances IDUA activity on fibroblasts from mucopolysaccharidosis I patients. Curr Pharm Biotechnol 2013; 14 (02) 194-198
• 67 Kamei M, Kasperski K, Fuller M. , et al. Aminoglycoside-induced premature stop codon read-through of mucopolysaccharidosis type I patient Q70X and W402X mutations in cultured cells. JIMD Rep 2014; 13: 139-147
• 68 Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA. α-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 2004; 338 (03) 453-462
• 69 Keeling KM, Wang D, Dai Y. , et al. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS One 2013; 8 (04) e60478
• 70 Bartolomeo R, Polishchuk EV, Volpi N, Polishchuk RS, Auricchio A. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis 2013; 36 (02) 363-371
• 71 Takai T, Higaki K, Aguilar-Moncayo M. , et al. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther 2013; 21 (03) 526-532
• 72 Hoshina H, Shimada Y, Higuchi T, Kobayashi H, Ida H, Ohashi T. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II. Mol Genet Metab 2018; 123 (02) 118-122
• 73 Fantur K, Hofer D, Schitter G. , et al. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts. Mol Genet Metab 2010; 100 (03) 262-268
• 74 Suzuki H, Ohto U, Higaki K. , et al. Structural basis of pharmacological chaperoning for human β-galactosidase. J Biol Chem 2014; 289 (21) 14560-14568
• 75 Thonhofer M, Weber P, Gonzalez Santana A. , et al. Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable β-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal β-galactosidase mutant R201C. Carbohydr Res 2016; 429: 71-80
• 76 Matos L, Canals I, Dridi L. , et al. Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis 2014; 9: 180
• 77 Pshezhetsky AV, Pan X, Héon-Roberts R. , et al. Chaperone therapy for mucopolysaccharidosis type IIIC. Mol Genet Metab 2018; 123: S121-S122
• 78 Malinowska M, Wilkinson FL, Langford-Smith KJ. , et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010; 5 (12) e14192
• 79 Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A. , et al. Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011; 17 (04) CR196-CR202
• 80 Delgadillo V, O'Callaghan MM, Artuch R, Montero R, Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011; 34 (05) 1039-1044
• 81 de Ruijter J, Valstar MJ, Narajczyk M. , et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012; 71 (01) 110-120
• 82 Kim KH, Dodsworth C, Paras A, Burton BK. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab 2013; 109 (04) 382-385
• 83 Frohbergh M, Ge Y, Meng F. , et al. Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. PLoS One 2014; 9 (06) e100882
• 84 Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH. Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010; 107 (01) 222-227
• 85 Schuchman EH, Ge Y, Lai A. , et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 2013; 8 (01) e54459
• 86 Simonaro CM, Tomatsu S, Sikora T. , et al. Pentosan polysulfate: oral versus subcutaneous injection in mucopolysaccharidosis type I dogs. PLoS One 2016; 11 (04) e0153136
• 87 Hennermann JB, Gökce S, Solyom A, Mengel E, Schuchman EH, Simonaro CM. Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis 2016; 39 (06) 831-837
• 88 Banecka-Majkutewicz Z, Jakóbkiewicz-Banecka J, Gabig-Cimińska M, Węgrzyn A, Węgrzyn G. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses. Arch Immunol Ther Exp (Warsz) 2012; 60 (06) 461-468
• 89 Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 2014; 39 (03) 215-224
• 90 Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 2007; 92 (1–2): 115-121
• 91 Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 2006; 60 (03) 309-314
• 92 Derrick-Roberts ALK, Jackson MR, Pyragius CE, Byers S. Substrate deprivation therapy to reduce glycosaminoglycan synthesis improves aspects of neurological and skeletal pathology in MPS I mice. Diseases 2017; 5 (01) 5
• 93 Giugliani R, Federhen A, Silva A. , et al. Emerging treatment options for the mucopolysaccharidoses. Res and Rep in Endocrine Disorders 2012; 2: 53-64
• 94 Hinderer C, Bell P, Louboutin JP. , et al. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. Mol Genet Metab 2016; 119 (1–2): 124-130
• 95 Ellinwood NM, Ausseil J, Desmaris N. , et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2011; 19 (02) 251-259
• 96 Whitley CB, McIvor RS, Aronovich EL. , et al. Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II). Hum Gene Ther 1996; 7 (04) 537-549
• 97 Holley RJ, Ellison SM, Fil D. , et al. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain 2018; 141 (01) 99-116